Age Range
18+
Trial Purpose
Inhloso yalolu cwaningo ukuhlola ukusebenza kahle nokuphepha kwe-opevesostat plus hormone replacement therapy (HRT) uma kuqhathaniswa nenye i-abiraterone acetate noma i- enzalutamide kubahlanganyeli abanomdlavuza wendlala yesinye we-Metastatic Castration-resistant (mCRPC) owake waphathwa ngomenzeli wamahomoni wesizukulwane esilandelayo (NHA). Imibono yocwaningo eyinhloko iwukuthi i-opevesostat iphakeme kunenye i-abiraterone acetate noma i- enzalutamide ngokuphathelene nokusinda kwamahhala kwe-radiographic (rPFS) ngeqembu le-Prostate Cancer Working Group (PCWG) Imibandela Yokuhlola Ukusabela Okuguquliwe Kuma-Solid Tumors (RECIST 1.1) njengoba ihlolwe yi-Blinded androgenval receptor (i-BICRval Independent) Isibuyekezo se-OS Ephakathi (i-BICRval Independent) kanye ne-OS Ephakathi isizinda esibophezelayo se-ligand (AR LBD) ukuguqulwa kwabahlanganyeli abalungile nabangalungile.
NATIONAL TRIAL REFERENCE NUMBER
I-NCT06136650
EU CT Number
2023-504957-11-00
When speaking to your doctor or clinical trial representative, please have the trial reference number available.
About The Study
Trial Phase
Trial start and end dates
- Actual study start date Disemba 18, 2023
- Estimated primary completion date Disemba 2, 2030
- Estimated study completion date Disemba 2, 2030